Current Infectious Disease Reports

, Volume 5, Issue 1, pp 85–92

Update on Kaposi’s sarcoma: A gammaherpesvirus-induced malignancy

  • Pallavi P. Kumar
  • Richard F. Little
  • Robert Yarchoan


Since the beginning of the AIDS epidemic, Kaposi’s sarcoma (KS) has been one of the most visible manifestations of this disease and one of the most distressing for affected patients. The discovery in 1994 of a new gammaherpesvirus, called Kaposi’s sarcoma-associated herpesvirus, has led to increased understanding of the pathogenesis of this disease and the potential for new specific therapy. In addition, the development of highly active antiretroviral therapy has had a substantial impact on the incidence of KS in countries where it is available and on the course of established disease. Finally, recent advances in our understanding of angiogenesis have the potential of leading to new KS therapies. In this article we review some of the recent advances in the epidemiology and pathogenesis of KS, review the current treatment of this disease, and discuss several therapeutic approaches that are now under development.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Stahl RE, Friedman-Kein A, Durbin R, et al.: Immunologic abnormalities in homosexual men: relationship to Kaposi’s sarcoma. Am J Med 1982, 73:171–178.PubMedCrossRefGoogle Scholar
  2. 2.
    Beral V, Peterman TA, Berkelman RL, Jaffe HW: Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990, 335:123–128.PubMedCrossRefGoogle Scholar
  3. 3.
    Antman K, Chang Y: Kaposi’s sarcoma. N Engl J Med 2000, 342:1027–1038. Excellent clinical and pathophysiologic review article of KS with discussion of epidemiology and treatment.PubMedCrossRefGoogle Scholar
  4. 4.
    Chang Y, Cesarman E, Pessin MS, et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994, 266:1865–1869.PubMedCrossRefGoogle Scholar
  5. 5.
    Moore PS, Chang Y: Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and without HIV infection. N Engl J Med 1995, 332:1181–1185.PubMedCrossRefGoogle Scholar
  6. 6.
    Gao S-J, Kingsley L, Zheng ML, et al.: KSHV antibodies among Americans, Italians, and Ugandans with and without Kaposi’s sarcoma. Nat Med 1996, 2:925–928.PubMedCrossRefGoogle Scholar
  7. 7.
    Whitby D, Howard MR, Tenant-Flowers M, et al.: Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet 1995, 346:799–802.PubMedCrossRefGoogle Scholar
  8. 8.
    Gallo RC: The enigmas of Kaposi’s sarcoma. Science 1998, 282:1837–1839.PubMedCrossRefGoogle Scholar
  9. 9.
    Cesarman E, Chang Y, Moore PS, et al.: Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related bodycavity-based lymphomas. N Engl J Med 1995, 332:1186–1191.PubMedCrossRefGoogle Scholar
  10. 10.
    Boshoff C, Weiss R: AIDS-related malignancies. Nat Rev Cancer 2002, 2:373–382. Excellent scientific overview of AIDS-related malignancies, including KS.PubMedCrossRefGoogle Scholar
  11. 11.
    Moore PS, Boshoff C, Weiss RA, Chang Y: Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996, 274:1739–1744.PubMedCrossRefGoogle Scholar
  12. 12.
    Boshoff C, Endo Y, Collins PD, et al.: Angiogenic and HIVinhibitory functions of KSHV-encoded chemokines. Science 1997, 278:290–294.PubMedCrossRefGoogle Scholar
  13. 13.
    Aoki Y, Yarchoan R, Wyvill K, et al.: Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood 2001, 97:2173–2176. Article describing measurement of KSHV-encoded viral IL-6 and its role in various KSHV-related malignancies.PubMedCrossRefGoogle Scholar
  14. 14.
    Aoki Y, Yarchoan R, Braun J, et al.: Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood 2000, 96:1599–1601.PubMedGoogle Scholar
  15. 15.
    Davis DA, Rinderknecht AS, Zoeteweij JP, et al.: Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 2001, 97:3244–3250. Article describing how KSHV can be activated by hypoxia and how this may account for some of the clinical manifestations of KS.PubMedCrossRefGoogle Scholar
  16. 16.
    Pauk J, Huang ML, Brodie SJ, et al.: Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2000, 343:1369–1377. Interesting article showing that KSHV is shed into the saliva and that this can be important in the spread of this virus.PubMedCrossRefGoogle Scholar
  17. 17.
    Plancoulaine S, Abel L, van Beveren M, et al.: Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet 2000, 356:1062–1065.PubMedCrossRefGoogle Scholar
  18. 18.
    Andreoni M, Sarmati L, Nicastri E, et al.: Primary human herpesvirus 8 infection in immunocompetent children. JAMA 2002, 287:1295–1300.PubMedCrossRefGoogle Scholar
  19. 19.
    Miles SA, Rezai AR, Salazar-Gonzalez JF, et al.: AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A 1990, 87:4068–4072.PubMedCrossRefGoogle Scholar
  20. 20.
    Varthakavi V, Browning PJ, Spearman P: Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi’s sarcoma-associated herpesvirus. J Virol 1999, 73:10329–10338.PubMedGoogle Scholar
  21. 21.
    Ensoli B, Barillari G, Salahuddin SZ, et al.: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients. Nature 1990, 345:84–86.PubMedCrossRefGoogle Scholar
  22. 22.
    Yarchoan R, Mitsuya H, Myers CE, Broder S: Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989, 321:726–738.PubMedCrossRefGoogle Scholar
  23. 23.
    Flexner C: HIV-protease inhibitors. N Engl J Med 1998, 338:1281–1292.PubMedCrossRefGoogle Scholar
  24. 24.
    Rabkin CS: AIDS and cancer in the era of highly active antiretroviral therapy (HAART). Eur J Cancer 2001, 37:1316–1319.PubMedCrossRefGoogle Scholar
  25. 25.
    Jones JL, Hanson DL, Dworkin MS, Jaffe HW: Incidence and trends in Kaposi’s sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000, 24:270–274.PubMedGoogle Scholar
  26. 26.
    Mocroft A, Katlama C, Johnson AM, et al.: AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 2000, 356:291–296.PubMedCrossRefGoogle Scholar
  27. 27.
    Ledergerber B, Egger M, Erard V, et al.: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999, 282:2220–2226.PubMedCrossRefGoogle Scholar
  28. 28.
    Eltom MA, Jemal A, Mbulaiteye SM, et al.: Trends in Kaposi’s sarcoma and non-Hodgkin’s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002, 94:1204–1210. Detailed and interesting study documenting the trends in a variety of AIDS-associated malignancies in the United States since the beginning of the AIDS epidemic.PubMedGoogle Scholar
  29. 29.
    Tam HK, Zhang ZF, Jacobson LP, et al.: Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002, 98:916–922.PubMedCrossRefGoogle Scholar
  30. 30.
    Yarchoan R, Broder S: Preliminary results on the use of dideoxynucleosides in the therapy of AIDS. In Vaccines 87: Modern Approaches to New Vaccines: Prevention of AIDS and other Viral, Bacterial, and Parasitic Diseases. Edited by Chanock RM, Lerner RA, Brown F, Ginsberg H. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1987:214–224.Google Scholar
  31. 31.
    Cattelan AM, Calabro ML, Aversa SM, et al.: Regression of AIDS-related Kaposi’s sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999, 35:1809–1815.PubMedCrossRefGoogle Scholar
  32. 32.
    Dupont C, Vasseur E, Beauchet A, et al.: Long-term efficacy on Kaposi’s sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d’information et de soins de l’immunodeficience humaine. AIDS 2000, 14:987–993.PubMedCrossRefGoogle Scholar
  33. 33.
    Bower M, Fox P, Fife K, et al.: Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. AIDS 1999, 13:2105–2111.PubMedCrossRefGoogle Scholar
  34. 34.
    Vaccher E, di Gennaro G, Nasti G, et al.: HAART is effective as anti-Kaposi’s sarcoma therapy only after remission has been induced by chemotherapy. J Acquir Immune Defic Syndr 1999, 22:407–408.PubMedGoogle Scholar
  35. 35.
    Tulpule A, Scadden DT, Espina BM, et al.: Results of a randomized study of IM862 nasal solution in the treatment of AIDSrelated Kaposi’s sarcoma. J Clin Oncol 2000, 18:716–723.PubMedGoogle Scholar
  36. 36.
    Noy A, Gill P: Angiogenesis inhibitor IM862 is ineffective against AIDS-KS in a randomized, placebo controlled trial. In Sixth International Conference on Malignancies in AIDS and Other Immunodeficiencies: Basic, Epidemiologic and Clinical Research. Bethesda: National Cancer Institute; 2002.Google Scholar
  37. 37.
    Wilkinson J, Cope A, Gill J, et al.: Identification of Kaposi’s sarcoma-associated herpesvirus (KSHV)-specific cytotoxic Tlymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol 2002, 76:2634–2640. Interesting article providing a detailed analysis of the cytotoxic T-cell responses to KSHV-encoded antigens and how this response is affected by HAART.PubMedCrossRefGoogle Scholar
  38. 38.
    Pati S, Pelser CB, Dufraine J, et al.: Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002, 99:3771–3779.PubMedCrossRefGoogle Scholar
  39. 39.
    Sgadari C, Barillari G, Toschi E, et al.: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002, 8:225–232.PubMedCrossRefGoogle Scholar
  40. 40.
    Bower M, Portsmouth S, Mandalia S, et al.: HIV-1 related Kaposi’s sarcoma (KS) in the highly active antiretroviral therapy (HAART) era. Non-nucleoside reverse transcriptase inhibitors (NNRTI’s) are as effective at preventing KS as protease inhibitors (PI’s). In Sixth International Conference on Malignancies in AIDS and Other Immunodeficiencies: Basic, Epidemiologic and Clinical Research. Bethesda: National Cancer Institute; 2002.Google Scholar
  41. 41.
    Rabkin CS, Janz S, Lash A, et al.: Monoclonal origin of multicentric Kaposi’s sarcoma lesions. N Engl J Med 1997, 336:988–993.PubMedCrossRefGoogle Scholar
  42. 42.
    Gill PS, Loureiro C, Bernstein-Singer M, et al.: Clinical effect of glucocorticoids on Kaposi’s sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989, 110:937–940.PubMedGoogle Scholar
  43. 43.
    Yarchoan R, Little R: AIDS-related malignancies. In Cancer: Principles and Practice of Oncology, edn 6. Edited by DeVita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams and Wilkins, 2001:2575–2596.Google Scholar
  44. 44.
    Northfelt DW, Dezube BJ, Thommes JA, et al.: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998, 16:2445–2451.PubMedGoogle Scholar
  45. 45.
    Welles L, Saville MW, Lietzau J, et al.: Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 1998, 16:1112–1121.PubMedGoogle Scholar
  46. 46.
    Tulpule A, Groopman J, Saville MW, et al.: Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002, 95:147–154.PubMedCrossRefGoogle Scholar
  47. 47.
    Sidell N, Taga T, Hirano T, et al.: Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol 1991, 146:3809–3814.PubMedGoogle Scholar
  48. 48.
    Walmsley S, Northfelt DW, Melosky B, et al.: Treatment of AIDS-related cutaneous Kaposi’s sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999, 22:235–246.PubMedGoogle Scholar
  49. 49.
    Miles SA, Dezube BJ, Lee JY, et al.: Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi’s sarcoma. AIDS 2002, 16:421–429.PubMedCrossRefGoogle Scholar
  50. 50.
    Martin DF, Kuppermann BD, Wolitz RA, et al.: Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999, 340:1063–1070.PubMedCrossRefGoogle Scholar
  51. 51.
    Mocroft A, Youle M, Gazzard B, et al.: Anti-herpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996, 10:1101–1105.PubMedCrossRefGoogle Scholar
  52. 52.
    Mazzi R, Parisi SG, Sarmati L, et al.: Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi’s sarcoma progression in two patients with AIDS. AIDS 2001, 15:2061–2062.PubMedCrossRefGoogle Scholar
  53. 53.
    Fife K, Gill J, Bourboulia D, et al.: Cidofovir for the treatment of Kaposi’s sarcoma in an HIV-negative homosexual man. Br J Dermatol 1999, 141:1148–1150.PubMedCrossRefGoogle Scholar
  54. 54.
    Little RF, Merced-Galindez F, Staskus K, et al.: A pilot study of cidofovir in patients with Kaposi’s sarcoma. J Infect Dis 2003, In press.Google Scholar
  55. 55.
    Little RF, Wyvill KM, Pluda JM, et al.: Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 2000, 18:2593–2602.PubMedGoogle Scholar
  56. 56.
    Pluda JM, Wyvill K, Little R, et al.: Preliminary results of a pilot study of the administration of interleukin-12 to patients (pts) with AIDS-associated Kaposi’s sarcoma (KS) [abstract 120]. J Hum Virol 1999, 2:200.Google Scholar
  57. 57.
    Cianfrocca M, Cooley TP, Lee JY, et al.: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi’s sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002, 20:153–159.PubMedCrossRefGoogle Scholar
  58. 58.
    Chang Y, Ziegler J, Wabinga H, et al.: Kaposi’s sarcoma-associated herpesvirus and Kaposi’s sarcoma in Africa. Uganda Kaposi’s Sarcoma Study Group. Arch Intern Med 1996, 156:202–204.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Pallavi P. Kumar
    • 1
  • Richard F. Little
    • 1
  • Robert Yarchoan
    • 1
  1. 1.HIV and AIDS Malignancy Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of HealthBethesdaUSA

Personalised recommendations